December 18, 2014

Oakland, CA

CTAF will assess the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the treatment of hepatitis C. The review will cover treatments under review by the FDA, including those developed by Gilead Sciences, Inc., AbbVie Inc., and Bristol-Myers Squibb Co.

Learn more or Register for this Meeting
Subscribe to Meetings